消化器内科 論文(2018年)
英語論文
| 著者 | タイトル | ジャーナル |
| Tomoya Yokota,Satoshi Hamauchi,Yukio Yoshida,Takashi Yurikusa,Miho Suzuki,Aiko Yamashita,Hirofumi Ogawa,Tsuyoshi Onoe,Keita Mori,Tetsuro Onitsuka | A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer | Support Care Cancer. |
| Tomoya Yokota,Takushi Yasuda,Hiroyuki Kato,Isao Nozaki,Hiroshi Sato,Yoshinori Miyata,Yoshifumi Kuroki,Ken Kato,Yasuo Hamamoto,Yasuhiro Tsubosa,Hirofumi Ogawa,Yoshinori Ito,Yuko Kitagawa | Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer | Int J Clin Oncol. |
| Yamazaki K, Taniguchi H, Yoshino T et al. | Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. | Cancer Sci. |
| Tomoya Yokota,Johanna Bendell,Patricia LoRusso,Takahiro Tsushima,Ved Desai,Hirotsugu Kenmotsu,Junichiro Watanabe,Akira Ono,Bhavani Murugesan,Joseph Silva,Tateaki Naito,Jonathan Greenberg,Prasanna Kumar,Yibin Wang,Takahiro Jikoh,Ryota Shiga,David M Hyman,Alan Loh Ho,David R Spriggs,Gary K Schwartz | Mrinal M GounderImpact of race on dose selection of molecular-targeted agents in early-phase oncology trials. | Br J Cancer. |
| Todaka A, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Nakamori S, Yachi Y, Henmi T, Kobayashi M, Boku N, Mori K, Fukutomi A. | Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. | Pancreas. |
| Tsushima T. P | Pancreatic Cancer and Biliary Cancer. Adjuvant Chemothereapy: Current Practices, Efficacy and Future Directions. | NOVA Science Publishers. |
| Kito Y, Machida N, Kawai S, Hamauchi S, Tsushima T, Todaka A, Yokota T, Yamazaki K, Fukutomi A, Onozawa Y, Tsuji K, Doyama H, Haraguchi Y, Nakashima K, Kunieda K, Taku K, Mori K, Yasui H. | Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer. | J Clin Oncol. |
| Tomoya Yokota,Masakuni Serizawa,Ayumu Hosokawa,Kimihide Kusafuka,Keita Mori,Toshiro Sugiyama,Yasuhiro Tsubosa,Yasuhiro Koh | PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue | BMC Cancer. |
| Masahiro Kawahira,Tomoya Yokota,Satoshi Hamauchi,Sadayuki Kawai,Yukio Yoshida,Yusuke Onozawa,Takahiro Tsushima,Akiko Todaka,Nozomu Machida,Kentaro Yamazaki,Akira Fukutomi,Hirofumi Yasui | Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. | Int J Clin Oncol. |
| Yoshino T, Yamazaki K, Shinozaki E et al | Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. | Clin Colorectal Cancer. |
| Kishida Y, Tsushima T, Endo M, Hamauchi S, Todaka A, Yokota T, Machida N, Yamazaki K, Fukutomi A, Onozawa Y, Yasui H. | Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer. | Am J Clin Oncol. |
| Kawakami T, Tsushima T, Omae K, Ogawa H, Shirasu H, Kito Y, Yoshida Y, Hamauchi S, Todaka A, Machida N, Yokota T, Yamazaki K, Fukutomi A, Onozawa Y, Yasui H. | Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study | BMC Cancer. |
| Shirasu H, Tsushima T, Kawahira M, Kawai S, Kawakami T, Kito Y, Yoshida Y, Hamauchi S, Todaka A, Yokota T, Machida N, Yamazaki K, Fukutomi A, Onozawa Y, Terashima M, Uesaka K, Yasui H. | Role of hepatectomy in gastric cancer with multiple liver-limited metastasesGastric Cancer. | Gastric Cancer. |
| Yen CJ, Muro K, Kim TW, Kudo M, Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC. | Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. | J Glob Oncol. |
| Yamazaki K, Taniguchi H, Yoshino T, Akagi K, Ishida H, Ebi H, Nakatani K, Muro K, Yatabe Y, Yamaguchi K, Tsuchihara K. | Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. | Cancer Sci. |
| Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. | Int J Clin Oncol. |
| Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E. | Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. | Clin Colorectal Cancer. |
| Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K | Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0). | Cancer Sci. |
| Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A. | A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. | Clin Colorectal Cancer. |
| Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y. | Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. | Oncologist. |
| Kojima T, Yamazaki K, Kato K, Muro K, Hara H, Chin K, Goddemeier T, Kuffel S, Watanabe M, Doi T. | Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors. | Cancer Sci. |
| Ishida H, Yamaguchi T, Tanakaya K, Akagi K, Inoue Y, Kumamoto K, Shimodaira H, Sekine S, Tanaka T, Chino A, Tomita N, Nakajima T, Hasegawa H, Hinoi T, Hirasawa A, Miyakura Y, Murakami Y, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Sugihara K, Watanabe T; Japanese Society for Cancer of the Colon and Rectum. | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version) | J Anus Rectum Colon |
| Narita Y, Kadowaki S, Oze I, Kito Y, Kawakami T, Machida N, Taniguchi H, Ura T, Ando M, Ito S, Tajika M, Yatabe Y, Yasui H, Muro K. | Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients | J Gastrointest Oncol |
| Furuta M, Yokota T. | [The Combination of Molecular Targeted Agents with Radiotherapy in Head and Neck Cancer] | Gan To Kagaku Ryoho |
| Zenda S, Yamaguchi T, Yokota T, Miyaji T, Mashiko T, Tanaka M, Yonemura M, Takeno M, Okano T, Kawasaki T, Nakamori Y, Ishii S, Shimada S, Kanamaru M, Uchitomi Y. | Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial | BMC Cancer |
| Shiba S, Imaoka H, Shioji K, Suzuki E, Horiguchi S, Terashima T, Kojima Y, Okuno T, Sukawa Y, Tsuji K, Umemoto K, Asagi A, Todaka A, Ueno M, Ikeda M, Morizane C, Furuse J. | Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study | BMC Cancer |
| Ikeda M, Ioka T, Fukutomi A, Morizane C, Kasuga A, Takahashi H, Todaka A, Okusaka T, Creasy CL, Gorman S, Felitsky DJ, Kobayashi M, Zhang F, Furuse J. | Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine | Cancer Sci |
| Yamamoto Y, Sugiura T, Todaka A, Okamura Y, Ito T, Ashida R, Kakuda Y, Nakanuma Y, Uesaka K. | Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value | World J Surg |
和文論文
| 著者 | タイトル | ジャーナル | |
| 安井博史、小野澤祐輔 | 静がんメソッド 消化器癌編 第2版 | 日本医事新報社 | |
| 安井博史 | 今日の治療指針 消化管癌の化学療法 | 医学書院 | （443－447）volume60 |
| 古田 光寛、山崎 健太郎 | 【大腸疾患 病態に基づく実地診療を目指して】治療 実地医家が知っておくべき治療の現状と進歩 大腸癌に対する化学療法 | Medical Practice | (0910-1551)35巻12号 Page1931-1936 |
| 白数 洋充、山﨑 健太郎 | Circulating tumor DNAの現状と展望 | 腫瘍内科 | (1881-6568)22巻5号 Page558-565 |
| 横田 知哉 | 【分子標的治療薬】頭頸部癌 | コンセンサス癌治療 | (1347-4618)15巻2号 Page88-92 |
| 横田 知哉 | 頭頸部におけるHPV感染 分子生物学、診断から治療まで | 診断病理 | (1345-6431)35巻4号 Page255-263 |
| 横田 知哉 | 【頭頸部がん・甲状腺がん・希少がん】頭頸部がん 頭頸部がんに対するafatinib(EGFR阻害薬)の開発状況(LUX-HN trialを中心に) | 腫瘍内科 | (1881-6568)22巻4号 Page380-385 |
| 白数 洋充、山﨑 健太郎 | 【消化管がん】Histology agnostic MSI-high固形腫瘍に対する抗PD-1抗体薬の国内外の現状と展望 | 腫瘍内科 | (1881-6568)22巻1号 Page9-16 |
| 横田 知哉 | 【ちょっと気になる頭頸部癌化学療法】再発・転移頭頸部扁平上皮癌に対する化学療法 二次治療以降の化学療法 プラチナ製剤に不適・不応例 | JOHNS | (0910-6820)34巻8号 Page1021-1023 |
| 町田 望 | TS-1の特徴と胃がん治療における役割(第3回) 胃がん術後補助化学療法におけるTS-1マネジメント | 胃がんperspective | (1883-3330)10巻1号 Page76-79 |
| 川上 武志、町田 望 | 【消化器癌に対する最新の集学的治療戦略】総論 化学療法(分子標的薬・免疫療法を含む) | 外科 | (0016-593X)80巻8号 Page793-797 |
| 古田 光寛、横田 知哉 | 【新規抗癌剤と放射線治療】頭頸部癌における分子標的薬と放射線療法との併用 | 癌と化学療法 | (0385-0684)45巻3号 Page419-423 |
| 福冨 晃 | 【BRとUR膵癌の最近のトピックス】切除不能膵癌に対する治療戦略の現状と課題 | 膵臓 | (0913-0071)33巻1号 Page37-47 |
| 横田 知哉 | 【頭頸部癌に対する薬物療法-最新情報】薬物同時併用放射線療法 | 耳鼻咽喉科・頭頸部外科 | (0914-3491)90巻3号 Page212-218 |